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Abstract
ERG gene rearrangements are found in about one half of all prostate cancers. Functional analyses do not fully explain the
selective pressure causing ERG rearrangement during the development of prostate cancer. To identify transcriptional
changes in prostate cancer, including tumors with ERG gene rearrangements, we performed a meta-analysis on published
gene expression data followed by validations on mRNA and protein levels as well as first functional investigations. Eight
expression studies (n = 561) on human prostate tissues were included in the meta-analysis. Transcriptional changes between
prostate cancer and non-cancerous prostate, as well as ERG rearrangement-positive (ERG+) and ERG rearrangement-
negative (ERG2) prostate cancer, were analyzed. Detailed results can be accessed through an online database. We validated
our meta-analysis using data from our own independent microarray study (n = 57). 84% and 49% (fold-change.2 and .1.5,
respectively) of all transcriptional changes between ERG+ and ERG2 prostate cancer determined by meta-analysis were
verified in the validation study. Selected targets were confirmed by immunohistochemistry: NPY and PLA2G7 (up-regulated
in ERG+ cancers), and AZGP1 and TFF3 (down-regulated in ERG+ cancers). First functional investigations for one of the most
prominent ERG rearrangement-associated genes - neuropeptide Y (NPY) - revealed increased glucose uptake in vitro
indicating the potential role of NPY in regulating cellular metabolism. In summary, we found robust population-
independent transcriptional changes in prostate cancer and first signs of ERG rearrangements inducing metabolic changes
in cancer cells by activating major metabolic signaling molecules like NPY. Our study indicates that metabolic changes
possibly contribute to the selective pressure favoring ERG rearrangements in prostate cancer.
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Introduction
About one half of all prostate cancers harbor a gene rearrange-
ment [1]. The latter is formed by fusion of 59 regulatory elements
of an androgen-regulated gene to the coding region of a member
of the E twenty-six (ETS) gene family of transcription factors. ETS
rearrangements result in androgen-driven over-expression of ETS
transcription factors [1]. The most common ETS rearrangement is
the translocation of the androgen-regulated transmembrane
protease serine 2 (TMPRSS2) gene, with the v-ets erythroblastosis
virus E26 oncogene homolog gene (ERG) transcription factor
accounting for about 85% of all ETS rearrangement-positive
prostate cancers [2–4]. ERG rearrangement is an early event in
the genesis of prostate cancer. It is already present in local low-
grade prostate cancer [5,6] and persists in metastatic and
castration-resistant types (CRPC) [1,4,7]. The early appearance
and the high frequency of ERG rearrangements indicate the
selective benefit of rearrangement-positive cells in prostate cancer.
Functional analyses performed thus far have not provided
a comprehensive explanation for the selective pressure forcing
ERG rearrangement in early stages of prostate cancer. ERG
rearrangement results in ERG overexpression [1]. The latter was
reported to promote cancer cell migration and invasion as well as
cellular dedifferentiation and transformation [8–11]. The role of
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ETS rearrangement in the progression of prostate cancer has also
not been clarified. While some studies indicate an association
between rearrangement-positive cancers, more aggressive tumors
and a poor prognosis (i.e. [12–14]), others report no such
association (i.e. [15–17]); some even report a favorable prognosis
(i.e. [18,19]). We obviously need more information about ETS
rearrangement-positive prostate cancers in order to understand
the biology of prostate cancer.
A large body of gene expression data has been published since
the procedure of expression analysis using microarrays was
established more than a decade ago [20]. These studies have
reported a variety of alterations in gene expression associated with
various diseases, including prostate cancer. Validation of the large
quantity of data obtained from gene expression experiments is
challenging. Just a small number of the identified candidates have
been functionally validated. These data are far from exhaustive
and still contain a lot of information awaiting exploitation. Meta-
analyses permit combined analyses of individual studies, are less
influenced by local findings, and allow reduction of data to achieve
robust results.
We present a meta-analysis on published gene expression data
with a view to identifying transcriptional changes in prostate
cancer. Our approach included comparison of prostate cancer
versus benign prostate tissue, and ERG rearrangement-positive
(ERG+) to ERG rearrangement-negative (ERG2) prostate
cancers. We validated the results of our meta-analysis using data
from an independent microarray study and confirmed selected
targets by immunohistochemistry. We also performed preliminary
functional investigations for one of the most prominent regulated
genes, namely neuropeptide Y (NPY). Our results indicate that
ERG-rearrangements possibly induce metabolic changes in cancer
cells by activating major metabolic signaling molecules such as
NPY.
Materials and Methods
Sample Cohorts
Tissue samples used for the meta-analysis are described
elsewhere (studies and references in Table 1). Tissue samples for
the validation expression study and immunohistochemical studies
were selected from the Innsbruck prostate cancer biobank. This
biobank was established in the course of the Tyrolean early
detection program for prostate cancer at the Department of
Urology, Innsbruck Medical University [21]. Written consent was
obtained from all patients and documented in the database of the
University Hospital Innsbruck in agreement with statutory
provisions and the requirements of the ethics committee of the
Innsbruck Medical University. The study was approved by the
ethics committee of the Innsbruck Medical University (Study no.
AM 3174, amendment 2). Cohorts analyzed here were the
following: a) Expression analysis validation study; 57 prostate
cancer tissues; GSC 5 n= 1, GSC 6 n= 5, GSC 7 n= 36, GSC 8
n=3, GSC 9 n=11, GSC 10 n= 1; patients’ age, mean 6
standard deviation (SD), 61.766.9 years; patients’ serum prostate
specific antigen (PSA) level, 7.465.0 ng/ml. b) Immunohisto-
chemical study; 93 prostate cancer tissues, GSC 5 n= 19, GSC 6
n=22, GSC 7 n= 32, GSC 8 n=10, GSC 9 n= 10; patients’ age,
mean 6 standard deviation (SD), 60.666.4 years; PSA level,
6.665.4 ng/ml.
Meta-analysis
We selected eight expression studies, comprising 561 human
prostate tissues, for the meta-analysis (Table 1, Figure S1). These
are listed in the databases Gene Expression Omnibus (http://
www.ncbi.nlm.nih.gov/geo) [22], Array Express (http://www.ebi.
ac.uk/arrayexpress) [23], and Oncomine (http://www.oncomine.
org) [24]. All studies were performed using the Affymetrix
microarray technology.
For integrative analysis of microarray data, raw data, as stored
in CEL files, was normalized using gcRMA algorithm [25,26]. For
detailed information about study-specific data preprocessing, see
supplementary methods. To perform a cross-study comparison of
gene expression levels, platform-specific gene probe-set identifiers
were mapped to a common namespace, as previously described
[27,28]. Here the platform-specific identifiers were mapped to
Entrez gene identifiers using the current probeset/Entrez map-
pings from BioMart via the biomaRt package [29]. Wherever
more than one probe-set was mapped to an Entrez gene identifier,
the probe-set with the highest variance was used for analysis. To
identify differentially regulated genes we used a two-step
approach. First, we derived combined p-values across the studies
using Fisher’s inverse chi-squared method [30]. We then
calculated combined (weighted) fold changes. In a previous study,
the authors used a permutation test to assess significance [27]. We,
on the other hand, derived the information from a chi-squared
distribution as suggested in [31]. See supplementary methods for
details about p-values and fold-change calculations. Functional
annotation clustering of the results of meta-analysis was performed
using the DAVID database (http://david.abcc.ncifcrf.gov) [32].
Validation Expression Analysis
An independent microarray data set (GSE32571) previously
generated by coauthors was used for validation of the ERG-
associated gene signature. For the present analyses, prostate cancer
tissues (n = 57) were assigned to the groups ERG+ and ERG2
using a break-apart fluorescent in situ hybridization (FISH) assay,
as described earlier [33]. Tissue samples were isolated by
macrodissection from 10-mm cryosections. Total RNA was
isolated with the EZ1 RNA Mini Kit (Qiagen) according to the
manufacturer’s instructions, checked for quality using the Agilent
2100 Bioanalyzer (Agilent Technologies), and quantified. Total
RNA was prepared for hybridization on Illumina Human Sentrix-
12 BeadChip arrays (Illumina) according to the manufacturer’s
recommendations. Illumina microarray data were processed using
the open source pipeline ‘‘Lumi’’ [34]. After quantile normaliza-
tion, differential expression of genes was determined using the R
package ‘‘LIMMA’’ [35]. Detailed methods and clinical data of
the expression validation study are described elsewhere [36].
Immunohistochemistry
Tissue slides (n = 10) and tissue microarrays (TMAs; n= 92;
diameter 0.6 mm) containing cancer (n = 3) and benign (n= 1)
cores of prostate tissue from prostate cancer patients were used for
immunohistochemical analysis. All tissue samples were stained for
ERG. Nine samples were excluded because of their small quantity
of tumor tissue. 24 tissues showed very weak or heterogeneous
ERG staining, whereas 69 tissues with intermediate to strong or
negative ERG staining were assigned to the groups ERG+ and
ERG2, respectively. 61 tissue samples were used for immunohis-
tochemical comparison of ERG+ and ERG2. Antigen retrieval
and immunohistochemistry were performed using a Discovery XT
automated slide-staining system (Ventana Medical Systems). All
target antibodies were tested on a test tissue microarray containing
different human tissue samples. Immunohistochemical staining
was evaluated by an experienced uropathologist (G.S.). Optimal
antigen retrieval conditions were established for all target
antibodies. Target antibodies, suppliers, article numbers, and
concentrations used were as follows: anti-AZGP1, Sigma, HPA-
Transcriptional Changes in ERG+ Prostate Cancer
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012582, 1:50; anti-ERG, Epitomics, EPR3864, 1:100; anti-
GPR116, Imgenex, IMG-71635, 1:100; anti-neuropeptide Y,
Abcam, ab30914, 1:200; anti-PLA2g7, Sigma, HPA-0035915,
1:400; anti-HPGD, Atlas, HPA004919, 1:75; anti-TFF3, Strategic
Diagnostics, 29940002, 1:5000. Antigen retrieval for all antibodies
was performed by heat pretreatment at 98uC for 1 hour in CC1,
a tris-based buffer with a slightly basic pH. Target antibodies were
incubated for 1 hour at 37uC, followed by iView DAB detection
(diaminobenzidine visualization, Ventana Medical Systems) and
hematoxylin counterstaining. Images were acquired using an Axio
Imager M1 microscope (Zeiss) and TissueFAXS software (Tis-
sueGnostics). Quantitative immunohistochemical analysis was
performed using the HistoQuest immunohistochemistry analysis
software (TissueGnostics), which is a cell-based staining intensity
analysis tool employing a nuclear cellular identification marker (in
this case hematoxylin), followed by quantitative analysis of a given
marker labeled in a different color (in this case cytoplasmatic
staining with diaminobenzidine, DAB, brown).
Cell Culture Experiments
DU145, DUCaP, LNCaP, PC3 and VCaP are derivatives of
prostate cancer metastases. These were purchased from ATCC
and cultured according to ATCC recommendations. EP156T and
RWPE-1 are immortalized benign prostate epithelial cells,
whereas CAF and PM151T are prostate stromal cells [37–39].
Benign and stromal cells were cultured as described earlier [37–
39]. The identity of cancer cell lines was confirmed by forensic
DNA fingerprinting methods employing the AmpFlSTRH SGM
PlusH PCR amplification kit (Applied Biosystems).
Cells were seeded in 24-well plates, serum starved, and treated
with 25 nM recombinant NPY/24 h (Sigma) for a total period of
48 hours. Total cell numbers were determined using the CASY
cell counter and analyzer system (Scha¨rfe System). Glucose levels
were measured in cell culture supernatants using the Gluc Cell
glucose monitoring system (Thermo Fisher Scientific). qPCR and
immunoblot were performed as described earlier [40].
Statistics
Statistical calculations for meta-analysis and validation expres-
sion analysis were conducted using the R (http://www.r-project.
org), packages from Bioconductor open source bioinformatics
database [41] and functions of MADAM [42].
Statistical calculations for immunohistochemistry and cell
culture experiments were performed using SPSS 18 for Windows.
The Kolmogorov–Smirnov test was used to investigate normal
distribution of data sets. Non-normally distributed data and data
with Gaussian (normal) distribution were analyzed using the
Mann–Whitney U-test and Student’s T-test, respectively, in order
to calculate the significance of differences between groups. P
values below 0.05 were considered significant. Error bars in the
histograms represent the standard deviation (SD) of a minimum of
three independent experiments.
Results
Meta-analysis on Published Gene Expression Data for
Prostate Cancer
To investigate changes in gene expression in human prostate
cancer, we performed a meta-analysis of published gene expres-
sion data. Eight independent microarray studies were included in
the meta-analysis, which consisted of 561 prostate tissue samples
(Table 1). The following two issues were investigated: a)
comparison of gene expression in prostate cancer tissues and
benign prostate tissues; and b) comparison of gene expression in
ERG rearrangement-positive (ERG+) and ERG rearrangement-
negative (ERG2) prostate cancers (study plan in Figure 1).
The results of our meta-analysis are shown in Figures 2A–B,
and listed in the Table S1A–B. Results of the meta-analysis and
the individual studies may also be viewed online at http://
Table 1. Gene expression studies included in the meta-analysis.
Study
Cancer (CA) vs. benign
(BE) ERG+ vs. ERG2 Ref. Source* Platform
n** CA n BE n ERG+ n ERG2
1 Bermudo 21 8 [68] AE E-MEXP-1331 Affymetrix GeneChip Human
Genome Focus Array
2 Chandran 57 15 20 19 [69] GEO GSE-6919 Affymetrix GeneChip Human
Genome U95Av2
3 Liu 41 13 14 13 [70] AE E-TABM-26 Affymetrix GeneChip Human
Genome HG-U133A
4 Singh 50 48 17 16 [71] O Singh Prostate Affymetrix GeneChip Human
Genome U95Av2
5 Tsavachidou 23 49 8 7 [72] AE E-MEXP-1327 Affymetrix GeneChip Human
Genome HG-U133A
6 Varambally 7 6 [73] GEO GSE3325 Affymetrix GeneChip Human
Genome U133 Plus 2.0
7 Wallace 68 14 23 22 [74] GEO GSE6956 Affymetrix GeneChip Human
Genome U133A 2.0
8 Wang 138 3 47 46 [75] GEO GSE8218 Affymetrix GeneChip Human
Genome HG-U133A
Total 405 156 129 123
The Affymetrix microarray technology was used in all of the studies.
*AE, Array Express; GEO, Gene Expression Omnibus; O, Oncomine; status 10/2010.
**n, number of samples used for the meta-analysis; samples that did not fulfill the quality criteria were excluded.
doi:10.1371/journal.pone.0055207.t001
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prostatedb.eigenlab.net/. In addition to the less conservative Chi-
squared method, which we applied for deriving a summary p-
value [31], the database also lists a more conservative summary p-
value derived by a permutational approach [27].
We first compared prostate cancer tissues with benign prostate
tissues. With regard to genes, which were at least 1.5-fold
regulated and revealed an adjusted p-value ,0.1, we found that
280 genes were up-regulated (46 of them more than 2-fold) while
275 genes were down-regulated (36 more than 2-fold) in prostate
cancer tissues compared to benign prostate tissues (Figure 2A,
Table S1A). Functional annotation revealed that differentially
regulated genes (fold-change .1.5) code for signaling molecules
(trans-membrane and extracellular signaling proteins), structural
proteins (cytoskeleton and cell adhesion proteins) and proteins
involved in proteolysis and wound healing (Figure 2C). Proteins
known to be associated with prostate cancer (e.g. AMACR [43],
AGR2 [44], CRISP3 [45], HPN [46], HOXC6 [47], OR51E2
[48]) as well as proteins not associated with prostate cancer thus far
(examples PPM1H, SLC4A4, CAMKK2) were identified in the
meta-analysis.
We then compared ERG+ and ERG2 prostate cancer tissues.
No information was available concerning the ERG rearrangement
status of the prostate cancer samples used in the studies of the
meta-analysis. ERG rearrangement results in ERG over-expres-
sion and is observed in about 50% of all prostate cancer tissues
[1,3]. We divided all prostate cancer samples of the studies
included in the meta-analysis into three groups, based on their
ERG expression level: ERG overexpression-positive samples,
ERG intermediate samples, and ERG overexpression-negative
samples (Figure S2). Each group consisted of one third of all
samples of one study. ERG overexpression-positive samples were
assumed to be ERG rearrangement-positive and assigned to the
ERG+ category, while ERG overexpression-negative samples were
assumed to be ERG rearrangement-negative and assigned the
ERG2 category. Samples assigned to the ERG intermediate
group were excluded from the analysis to ensure accurate
comparison of ERG+ and ERG2 prostate cancer samples. The
use of ERG expression as a surrogate for gene rearrangement-
status has been described earlier [49] and was verified in our own
microarray study as described below. The comparative meta-
analysis revealed 109 up-regulated and 58 down-regulated genes
(fold-change .1.5; adjusted p-value ,0.1; 36 genes were more
than 2-fold regulated) in ERG+ as compared to ERG2 prostate
cancer (Figure 2B, Table S1B). Differentially regulated genes were
related to the functional clusters signaling (extracellular signaling
peptides and hormone signaling), adhesion (cell adhesion and
extracellular matrix proteins), and defense response (wound
healing and inflammatory response; Figure 2D).
Our meta-analysis revealed changes in gene expression in
various subgroups during the development of prostate cancer. A
number of studies comprising independent patient cohorts were
included in the analysis. Therefore, the identified alterations in
gene expression signify general population-independent effects
related to prostate cancer.
Meta-analysis Validation by Independent Expression
Analysis
We then validated the results of our meta-analysis. We focused
on a comparison of ERG+ and ERG2 prostate cancers because
these subtypes were described recently and have not been
extensively investigated so far. For validation of the meta-analysis
we used data from an independent expression study performed on
an alternative expression platform (Illumina). The validation study
differs from the meta-analysis studies in the following aspects: a)
independent patient cohort (n = 57) selected from the Innsbruck
prostate cancer biobank; b) alternative gene expression technology
(validation study, Illumina BeadChip arrays; meta-analysis studies,
Affymetrix GeneChip microarrays); and c) ERG+ and ERG2
group assignment (Figure 3A). In the meta-analysis, ERG+ and
ERG2 tissues were assigned according to ERG expression levels.
In the validation study the ERG rearrangement-status was
determined by fluorescence in situ hybridization using a break-
apart assay as described earlier [33] (Figure S3A).
We first confirmed that ERG rearrangement resulted in ERG
over-expression (Figure 3B, Figure S3A–C), thus indicating that
the ERG+ and ERG2 groups were correctly assigned in the meta-
analysis as well as the validation study. We then analyzed the
expression of the 155 genes (12 genes were excluded because of
missing or redundant probe sets) identified as being differentially
regulated in ERG+ and ERG2 tissues in the meta-analysis (FC
.1.5; p,0.1). 49% (76/155) of all genes found to be differentially
regulated in ERG+ and ERG2 prostate cancer in the meta-
analysis were verified in the validation study. When the validation
analysis was confined to genes which were regulated at least 2-fold
in the meta-analysis, these amounted to 84% (27/32) (Figure 3C–
D, Table S2). When we analyzed the validation expression study
as an independent study and investigated all genes in the arrays,
these still amounted to 20% and 41% for FC.1.5 and FC.2,
respectively (Table S2). The concordance between the meta-
analysis and the independent validation study showed that our
meta-analysis generated robust results which were independent of
the sample cohort, sample assignment, and employed gene
expression technology.
Protein Analysis Using Immunohistochemistry
Our study had been focused on mRNA expression levels until
this time. We then investigated whether proteins encoded by the
differentially regulated genes are found in different quantities in
Figure 1. Study protocol. Meta-analysis was performed on eight
independent gene expression studies focusing human prostate tissues.
Two types of comparative analyses were used. Genes showing
differentially regulated ERG+ and ERG2 prostate cancer tissues were
validated using an independent gene expression analysis (first
validation) and immunohistochemical staining (second validation; only
for selected genes).
doi:10.1371/journal.pone.0055207.g001
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Figure 2. Results of the meta-analysis. Genes differentially regulated in prostate cancer and benign prostate tissue (A, C), and ERG+ and ERG2
prostate cancer tissue (B, D). A–B) volcano plots. Differentially regulated genes were highlighted when at least 2-fold down- (green) or up-regulated
(red), and had an adjusted p-value smaller than 0.1. C–D) Graphic diagram of the eight top-ranked functional clusters determined by functional
annotation clustering, using the DAVID database. The size of the clusters correlates with the number of identified proteins associated with functional
annotation (fold-change .1.5). When proteins are present in more than one cluster, the clusters are connected by lines. The thickness of the
connecting lines reflects the number of proteins present in both connected clusters. Data concerning 561 tissue samples were used for the meta-
analysis.
doi:10.1371/journal.pone.0055207.g002
Transcriptional Changes in ERG+ Prostate Cancer
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ERG+ and ERG2 prostate cancer tissues. We selected in-
dependent tissues (not used for expression analysis) from the
Innsbruck prostate cancer biobank in order to further ensure that
our investigation would reveal general ERG+ prostate cancer-
related alterations rather than patient-specific differences.
To assign the tissues to the groups ERG+ and ERG2, we
determined ERG protein levels by immunohistochemistry using
an antibody previously specified for this application [50]. ERG
immunohistochemistry permitted a clear distinction between
ERG+ and ERG2 tissues. In agreement with published data
concerning ERG+ tissues, the staining intensity of ERG varied
from strong to weak (Figure S4A) [50]. Some tissues appeared
heterogeneous for ERG. Both ERG-positive and ERG-negative
cancer cells were present in these tissues (Figure S4B). Staining
controls were performed on a) benign prostate cells, which are
negative for ERG (Figure S4C, left image); b) endothelial cells and
lymphocytes, which stain positive for ERG [50] and constitute an
internal staining control (example in Figure S4C, right image); and
Figure 3. Validation of the meta-analysis. 84% of all genes found to be differentially regulated in ERG+ and ERG2 tissues (fold-change.2) were
verified by an independent expression study. A) Study characteristics. B) ERG expression levels in ERG rearrangement-positive and -negative tissue of
the validation study. ERG rearrangements were determined by fluorescent in situ hybridization. C) Genes differentially regulated in ERG+ and ERG2
tissues. D) Validated regulated genes in the meta-analysis and the validation study. P-value corrected BH; Fisher’s combined p-value, Benjamini-
Hochberg corrected.
doi:10.1371/journal.pone.0055207.g003
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c) cell lines representing ERG+ (VCAP) or ERG2 (Du145)
prostate cancer (Figure S4D). In line with previous reports,
approximately one half (here 60%) of all investigated prostate
tissues appeared ERG-positive (summary of 93 prostate cancer
cases in Figure S4E) [1,3]. To reflect the meta-analysis, tissues with
high to intermediate ERG staining were compared to tissues with
negative ERG staining; tissues with heterogeneous and low ERG
staining were excluded.
Six target genes were subjected to protein validation:
GPR116, NPY and PLA2G7, three genes over-expressed in
ERG+ tissues, and AZGP1, HPGD and TFF3, three genes down-
regulated in ERG+ prostate cancer tissues. In four of the tested
genes, the protein levels reflected the regulation of the mRNAs:
NPY and PLA2G7 were up-regulated in ERG+ tissues while
AZGP1 and TFF3 appeared down-regulated (Figure 4). TFF3
has been reported to be differentially regulated in ERG+ tissues
[51]; therefore only 11 samples were used for comparison. In
line with our data, PLA2G7 was recently reported to be related
to ERG+ tumors [52]. Protein levels of the target genes GPR116
and HPGD were not altered on comparison of ERG+ and
ERG2 prostate cancer (data not shown). It remains unclear
whether the discrepancies observed between mRNA and protein
levels of these two genes reflect biological (different regulation at
mRNA and protein level) or technical (antibody performance)
variations.
ERG-associated Expression of NPY Induces Increased
Glucose Uptake in Prostate Cancer Cells
To gain new insights about the role of ERG-rearrangements in
prostate cancer, we investigated the functions of differentially
regulated genes in ERG+ prostate cancer cells. NPY was selected
for functional analysis. NPY is a small neuropeptide with was
described as a central regulator of energy balance in the human
body (reviewed in [53]). We measured glucose uptake in vitro to
determine whether NPY induces metabolic changes in prostate
cancer cells.
We confirmed NPY overexpression in ERG+ prostate cancer
cell lines using qPCR and immunoblotting. qPCR expression
levels of NPY revealed highest expression of NPY mRNA in the
ERG+ cell lines DUCaP and VCaP compared to other prostate
cell lines (Figure 5A). NPY protein was detectable by immuno-
blotting solely in DUCaP and VCaP (Figure 5B). When we treated
prostate cancer cells which do not express endogenous NPY
(DU145, LNCaP and PC3) with recombinant NPY (48 h, 25 nM),
we observed greater glucose uptake in NPY-treated cells than in
untreated cells (Figure 5C). This effect was not observed in cells
expressing endogenous NPY (VCaP, Figure 5C). To investigate
whether human prostate tissues are potentially NPY responsive,
we finally compared the expression of NPY and the NPY-
responsive receptors NPY1R, NPY5R and NPY2R (NPY affinity
ranked, [54]) in the prostate with those in other human organs,
using the Oncomine database (http://www.oncomine.org) [24].
We found NPY to be more abundant in benign and cancerous
prostate tissue compared to benign and cancerous tissues derived
from other organs while NPYRs were expressed to a similar extent
in prostate and other tissues (representative studies are shown in
Figure S5). Thus, several tissues might be NPY responsive. The
prostate, however, produces significant levels of endogenous NPY.
Taken together our data demonstrate that ERG-rearrangements
in prostate cancer are associated with a variety of transcriptional
changes in cancer cells including the expression of metabolic
sensors like NPY.
Discussion
This study was performed to determine changes in gene
expression in prostate cancer, which are due to general alterations
related to prostate and independent of patient cohorts, technical
variations, and the applied methodology. We focused on
transcriptional changes in ERG rearrangement-positive (ERG+)
prostate cancer, because these tumors constituted a less-charac-
terized subgroup of prostate cancers. We expected the results of
this investigation to yield a publicly accessible database for gene
expression alterations in prostate cancer and provide new insights
into the biology of ERG+ prostate cancers. We observed, for the
first time, that ERG rearrangements are possibly associated with
metabolic changes in prostate cancer cells.
Our meta-analysis consisted of 561 tissues derived from eight
independent studies. We performed two comparisons in the meta-
analysis (cancer vs. benign prostate tissue and ERG+ vs. ERG2
prostate cancer) so that the study would be of interest to a large
scientific community. We validated the investigation using our
own independent gene expression study performed on an in-
dependent patient cohort, employing an alternative gene expres-
sion method. The large numbers of validated genes (84%,
comparison ERG+ vs. ERG2, cutoff of fold change .2) indicated
that our meta-analysis had generated robust results. The
alterations in gene expression in prostate cancer we describe here
represent therefore general population-independent transcription-
al changes in prostate cancer.
Interestingly, we identified many genes differentially regulated
in ERG+ prostate cancer, which proteins were previously
described as diagnostic or prognostic prostate cancer biomarkers,
like AZGP1 [55,56], APOD [57,58], CRISP3 [45], NPY [59] and
TFF3 [60]. Many of these putative prostate cancer markers were
not successfully validated and translated into clinics. Our study
indicates that these proteins possibly present ERG+ prostate
cancer rather than general prostate cancer markers.
Transcriptional changes in prostate cancer probably exceed
those identified in the present meta-analysis. The studies we used
were published several years ago. The authors used gene chip
technologies, which covered just a subset of all human genes. The
stringent conditions required for a valuable meta-analysis led to
further exclusion of several gene probes, which were measured in
just a few studies or demonstrated high background variations.
Finally, the tissue samples used in the studies were taken from
whole tumor tissue, including stromal fractions. High stromal
expression of certain genes may mask regulations occurring in
epithelial tissue. Despite these limitations, published gene expres-
sion studies proved to be a very precious source of data, especially
for meta-analysis. They were also useful for analyzing research
questions the studies were not originally designed to address.
Besides, much more information may yet be obtained from these
studies.
We used the data to advance our current understanding of the
biology of prostate cancer while focusing on the biology of ERG+
prostate cancer. Functional analyses performed thus far have been
unable to fully explain the selective pressure forcing ERG
rearrangement in early stages of prostate cancer. Apart from
a pronounced migratory and dedifferentiated phenotype [8–11],
ERG-related cancer-promoting functions remained largely un-
defined. We observed a variety of lipoproteins, phospholipases (e.g.
APOD, PLA1A, PLA2G4C, PLA2G7), and several small secretory
molecules with described metabolic functions (e.g. NPY, RLN1,
RLN2) in our top-ranked ERG+ regulated genes. We speculated
that ERG rearrangements induce metabolic changes in prostate
cancer cells. We selected NPY, a factor highly overexpressed in
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ERG+ tumors, for functional analysis. NPY has been described as
a potent orexigenic agent (reviewed in [53]). Investigations
concerning the function of NPY in prostate cancer have been
confined to proliferation and migration studies. These report weak
effects of NPY on migration and cell-line-specific differences on
cell proliferation [61–63]. When treating prostate cancer cells with
Figure 4. Immunohistochemistry for proteins coded by differentially regulated genes in ERG+ and ERG2 prostate cancer. A)
Consecutive slides of prostate tissues of two representative patients. B) Quantification of tissue specimens obtained from 61 different prostate cancer
patients using the immunohistochemistry quantification software HistoQuest. HistoQuest does not distinguish between epithelial and stromal cells.
Differences in staining intensity in epithelial cells exceed the differences shown in the box-blots. Bar, 100 mM. Statistics, Mann Whitney U-test;
*,p,0.05; **p,0.01; ***p,0.001.
doi:10.1371/journal.pone.0055207.g004
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NPY, we observed higher glucose uptake in NPY-treated cells.
Our data indicate that NPY mediates metabolic functions in
prostate cancer cells. As NPY is overexpressed in ERG+ prostate
cancer cells, these data provide first signs of the fact that ERG
rearrangements in prostate cancer possibly modulate metabolic
functions through expression of metabolic regulators like NPY.
Apart of its function as an orexigenic agent, NPY was also
shown to be involved in stress response, pain perception and
regulation of bone homeostasis and turnover [64,65]. As prostate
cancer metastasizes preferentially to the bone, the latter is of
special interest. Most prostate cancer bone metastases are
characterized by a disrupted bone homeostasis and bone loss
( = osteolytic phenotype, for recent review see [66]). Disrupted
bone homoeostasis and bone loss caused by reduced osteoblast
activity were also described when elevated levels of NPY are
present in the bone microenvironment (reviewed in [64]). NPY
represses osteoblast activity. Thus, one major factor expressed by
prostate cancer cells and modulating the bone microenvironment
may be NPY. As NPY is highest expressed in ERG+ prostate
cancers it would be interesting to investigate whether ERG+ differ
from ERG2 prostate cancer bone metastases. So far, data on
ERG rearrangement and prostate cancer progression are very
inconsistent, reporting a positive [12–14,67], no [15–17] or even
a negative [18,19] correlation.
In the present studywe investigatedERGrearrangement,which is
themost commontypeofETSrearrangement. Further studieswill be
needed to determine whether other ETS rearrangements involving
ETV1, ETV4, ETV5 or ELK4 exert similar effects as ERG does.
In summary, the present study was focused on population-
independent transcriptional changes in prostate cancer and give
first hints that ERG rearrangement in prostate cancer induces
metabolic changes. Selective pressures favoring ERG rearrange-
ment in prostate cancer presumably include enhanced migration,
invasion, and dedifferentiation of prostate cancer cells, as well as
exert an impact on energy balance, availability and consumption.
Supporting Information
Figure S1 Prisma Flow Diagram.
(PDF)
Figure S2 Definition of ERG+ and ERG2 prostate
cancer tissues based on their ERG expression levels.
(PDF)
Figure S3 ERG rearrangement results in ERG over-
expression.
(PDF)
Figure S4 ERG immunohistochemistry.
(PDF)
Figure S5 Expression of NPY and NPY-responsive
receptors.
(PDF)
Table S1 Genes differentially regulated in prostate
cancer determined in a meta-analysis of published gene
expression data.
(XLS)
Table S2 Validation of genes differentially regulated in
prostate cancer determined by meta-analysis using an
independent expression analysis.
(XLS)
Methods S1 Meta-analysis: preparation of data, statis-
tical calculations.
(DOC)
Acknowledgments
We thank all authors of the gene expression studies used for this meta-
analysis for providing publicly available data concerning their studies. We
thank Irma Sottsas and Birgit Stenzel for their excellent technical support;
Walther Parson for forensic DNA fingerprinting; Ruth Pfeiffer for statistical
advice; as well as Francesca Demichelis, Mark Rubin and Matthias
Dehmer for fruitful discussions.
Author Contributions
Conceived and designed the experiments: PM KK AG HS HK. Performed
the experiments: PM KK KU RK LM MF GS CS SE IV HK. Analyzed
the data: PM KK RK LM MF GS AG HS HK. Contributed reagents/
materials/analysis tools: PM KK RK GS AG HS HK. Wrote the paper:
PM KK HK.
Figure 5. Neuropeptide Y (NPY) is up-regulated in ERG+
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